9B7R

Fab3-1 in complex with the capsid of Adeno-associated virus type 9

9B7R の概要

• エントリーDOI: 10.2210/pdb9b7r/pdb
• EMDBエントリー: 44321
• 分子名称: Capsid protein VP1, Fab3-1 heavy chain, Fab3-1 light chain (3 entities in total)
• 機能のキーワード: adeno-associated virus, aav, capsid, fab-complex, antibody, nab, viral protein-immune system complex, viral protein/immune system
• 由来する生物種: Adeno-associated virus; 詳細
• タンパク質・核酸の鎖数: 8
• 化学式量合計: 384645.64

構造登録者

Mietzsch, M.,McKenna, R. (登録日: 2024-03-27, 公開日: 2025-04-02, 最終更新日: 2025-05-14)

主引用文献

Mietzsch, M.,Hsi, J.,Nelson, A.R.,Khandekar, N.,Huang, A.M.,Smith, N.J.,Zachary, J.,Potts, L.,Farrar, M.A.,Chipman, P.,Ghanem, M.,Alexander, I.E.,Logan, G.J.,Huiskonen, J.T.,McKenna, R.
Structural characterization of antibody-responses following Zolgensma treatment for AAV capsid engineering to expand patient cohorts.
Nat Commun, 16:3731-3731, 2025

PubMed Abstract: Monoclonal antibodies are useful tools to dissect the neutralizing antibody response against the adeno-associated virus (AAV) capsids that are used as gene therapy delivery vectors. The presence of pre-existing neutralizing antibodies in large portions of the human population poses a significant challenge for AAV-mediated gene therapy, primarily targeting the capsid leading to vector inactivation and loss of treatment efficacy. This study structurally characterizes the interactions of 21 human-derived neutralizing antibodies from three patients treated with the AAV9 vector, Zolgensma®, utilizing high-resolution cryo-electron microscopy. The antibodies bound to the 2-fold depression or the 3-fold protrusions do not conform to the icosahedral symmetry of the capsid, thus requiring localized reconstructions. These complex structures provide unprecedented details of the mAbs binding interfaces, with many antibodies inducing structural perturbations of the capsid upon binding. Key surface capsid amino acid residues were identified facilitating the design of capsid variants with antibody escape phenotypes. These AAV9 capsid variants have the potential to expand the patient cohort to include those that were previously excluded due to their pre-existing neutralizing antibodies against the wtAAV9 capsid, and the possibly of further treatment to those requiring redosing.

PubMed: 40253479
DOI: 10.1038/s41467-025-59088-4

実験手法

ELECTRON MICROSCOPY (3.02 Å)